Stephen Liu

FDA Approval: Taletrectinib and ROS1 NSCLC | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for ...

A new ROS1+ NSCLC therapy is here.
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.

🎧 Tune in here: bit.ly/FDATaletrect...

#IASLC #NSCLC

Virtual Tumor Board: Resectable EGFR NSCLC | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explor ...

What’s the best approach to resectable EGFR-mutant NSCLC?
In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario.

🎧 bit.ly/VTBregfrnsclc

#NSCLC #EGFR

FDA Approval: Sunvozertinib in EGFR Exon 20 NSCLC | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses EGFR exon 20 insertions and the recently approved targeted therapy for this subset of ...

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy.

🎧 bit.ly/FDAexon20

Last chance! 🕐 Early bird registration for #WCLC25 ends today.

Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer.

✨ Discounted rates
✨ Global networking
✨ Cutting-edge research

Register today → wclc.iaslc.org/registration/

#IASLC #LungCancer #OncologyConference

Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.

New Podcast: BTOG does … Tobacco Dependency in Lung Cancer.

Dr Emma O’Dowd talks to Professor Sanjay Agrawal.

Wherever you get your podcasts or listen online
btog.org/btog-podcasts/

#LCSM #LungCancer

ASCO 2025 Highlights | IASLC This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...

From HERTHENA-Lung02 to CheckMate 816, the latest #LungCancerConsidered episode breaks down major #ASCO25 lung cancer studies. Join @narjustflorezmd.bsky.social, @stephenvliu.bsky.social, @patrickforde.bsky.social and Dr. Charu Aggarwal for expert insights.

🎧 bit.ly/ASCO25LCC

#NSCLC #SCLC

Join Dr. Noemi Reguart, Dr. Nicolas Girard, and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar, where we will discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data!

us06web.zoom.us/webinar/regi...

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adv...

Proud to be part of the phase III IMforte team - the addition of maintenance lurbinectedin to standard maintenance atezolizumab for patients with #SCLC led to an improvement in PFS (HR 0.54) and an improvement in survival (OS HR 0.73), published in @thelancet.com.

www.thelancet.com/journals/lan...

Congratulations to the newly elected SITC At-Large Directors - Drs. Tina Cascone, Aurelien Marabelle, and Ryan Sullivan! New SITC leadership joining an accomplished board in moving immunotherapy forward with the goal of long term survival for all of our patients! @sitcancer.bsky.social

ASCO 2025 Highlights | IASLC This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...

Lots of lung cancer updates at #ASCO25. Listen to the latest episode of Lung Cancer Considered, the @iaslc.bsky.social podcast, for a discussion on highlights with Drs. @narjustflorezmd.bsky.social, Charu Aggarwal, @patrickforde.bsky.social and me. #LCSM

www.iaslc.org/iaslc-news/l...

Virtual Tumor Board: Targeting Residual Disease | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Car ...

In the latest #LungCancerConsidered episode, @stephenvliu.bsky.social moderates a discussion featuring Dr. Mara Antonoff, Dr. Shankar Siva & Dr. David Carbone. They navigate a real-world case & explore current approaches to treatment & clinical decision-making.

🎧 Listen here: bit.ly/VTBresidual

FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCL ...

The FDA has approved telisotuzumab vedotin for MET+ NSCLC! On this #LungCancerConsidered episode, @stephenvliu.bsky.social, Dr. Mor Moskovitz and Dr. Jonathan Goldman break down what this means for lung cancer care.

🎧 Listen now: bit.ly/FDATVandMET

#LungCancer #NSCLC

Interview with Dr. Bryant Lin: Teaching My Lung Cancer | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Dr. Bryant Lin, Clinical Professor of Medicine at Stanford University and co-founder ...

After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care.

🎧 Listen: bit.ly/LinTMLC

To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!

www.sitcancer.org/membership/2...

To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!

www.sitcancer.org/membership/2...

Microbiome and Immunotherapy for NSCLC | IASLC This episode of Lung Cancer Considered takes an in-depth look at the microbiome-- what is it, and why is it important to lung cancer clinicians and researchers? ...

On the new episode of #LungCancerConsidered, we dive into how the microbiome impacts lung cancer & immunotherapy. @stephenvliu.bsky.social talks with Drs. Arielle Elkrief & Bertrand Routy about what we know and what we don’t.

🎧 Listen now: bit.ly/MI-NSCLC
#LungCancer #Immunotherapy

Virtual Tumor Board: Stage III ALK+ NSCLC | IASLC This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now si ...

🎙️ Don't miss this all-new episode of #LungCancerConsidered! Host @stephenvliu.bsky.social continues our #VirtualTumorBoard series with a complex Stage III ALK+ #NSCLC case. How should clinicians approach this patient? Listen now for expert insights! 🎧 bit.ly/VTBsIIIALK

#ALKPositive #IASLC

Amid funding concerns, promising lung cancer vaccines could be available in next few years - WTOP News Clinical trials to develop a lung cancer vaccine to treat or prevent the most deadly form of cancer in the U.S. could be available in “the next few years.”

Disclosure: For someone like me, who was dx w stage 4 #lungcancer in 2022 and have been cancer-free for 2 years, a cancer vaccine is one of the most promising ways to prevent cancer from coming back. Always a pleasure to learn from @stephenvliu.bsky.social. #lcsm #oncosky wtop.com/drugs-and-me...

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

Great session on systemic therapy for SCLC by @stephenvliu.bsky.social at #BTOG23

➡️ BiTE engages, ADCs and many other agents showing promise
➡️ Possible role for radioligands
➡️ New never smokers phenotype emerging
➡️ Many reasons to be hopeful!

@drjnaidoo.bsky.social
@tnewsomdavis.bsky.social

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC

➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy.

➡️ Continued evidence of a benefit from PCI in LS-SCLC

Photo of Dr Stephen Liu w slide on his he novel agents for small cell lung cancer

Photo of Dr Stephen Liu at Btog stage w slide describing small cell lung cancer in people who never smoked

Packed house at #BTOG25’s SC lung cancer session

Dr @stephenvliu.bsky.social talks of need to ID those that do/don’t derive benefit, find biomarkers, review optimal sequencing & better understand evolving biology of #SCLC. Describes SCLC in ppl w no/light smoking history.

#LCSM @btog.bsky.social

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25

@stephenvliu.bsky.social: SCLC, ADCs

❇️ TROP2: has potential, respectable 40% ORR

❇️ SEZ6: impressive depth of response, but early days

❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD

But exciting developments:
There is a New Hope in SCLC

Superstar #BTOG25 speakers, and the boss

Always an interesting podcast with @stephenvliu.bsky.social
"Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance" via @iaslc.bsky.social
https://buff.ly/3QuhOTA

2025 Texas Lung Cancer Conference Agenda 2025 Texas Lung Cancer Conference Agenda

The full agenda for the Texas Lung Cancer Conference is live! Join us April 10-12, 2025 at Austin City Limits for the IASLC-endorsed CME meeting covering all things lung cancer with an amazing faculty roster & agenda!

Register now for #TexasLung25 & see you there!

thetlcconference.com/agenda-2025/